Rovi/ROVI

€79.58

0%
-
1D1W1MYTD1YMAX

About Rovi

Laboratorios Farmaceuticos ROVI SA (ROVI) is a Spain-based company principally engaged in the pharmaceutical industry. The Company’s main activities include the development and commercialization, nationwide and abroad, of medicines and drugs. Its products are structured into three fields: Diagnostic, which offers contrast mediums for use in magnetic resonance, ultrasound and X-ray diagnostics; Prescription, which distributes medicines under such brands as Hibor, Osseor, Hepadren, Pneumovax-23, Glufan, Corlentor, Exxiv, Calcio y Vitamina D3 Rovi and Absorcol, among others; and Over The Counter (OTC), which comprises the Perspirex, Enerzona, Dentimelo and ColdPack brands. The Company owns such fully consolidated subsidiaries as Gineladius SL, Frosst Iberica SA, Rovi Contract Manufacturing SL and Bertex Pharma GmbH, among others.

Ticker

ROVI

Sector

Healthcare

Trading on

BME

Industry

Biotechnology & Drugs

CEO

Juan Lopez-Belmonte Encina

Employees

2,111

Headquarters

Madrid, Spain

Rovi Metrics

BasicAdvanced
€4.35B
Market cap
25.10
P/E ratio
€3.20
EPS
0.58
Beta
€1.10
Dividend rate
1.61%
Dividend yield
€4.35B
0.57515
€83.55
€37.96
77.65K
€1.10
2.549
0.857
9.685
12.13
33.58%
32.237
20.29%
32.16%
28.88%
25.105
5.239
7.729
8.597
74.847
1.68%
1.37%
1.61%
1.44%
-14.24%
25.47%
42.68%
42.53%

What the Analysts think about Rovi

Analyst Ratings

Majority rating from 9 analysts.
Buy

Price Targets

Average projection from 9 analysts.
5.27% downside
High €93.00
Low €66.00
€79.58
Current price
€75.39
Average price target

Rovi Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
23.09% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
€448.6M
109.63%
Net income
€103.6M
98.85%
Profit margin
23.09%
-5.14%

Rovi Earnings Performance

No data availble
Quarterly data is not available. You can look at the annual data instead.

Earnings per share (EPS)

Company profitability
-
QuarterlyAnnual
Actual
Expected
Surprise
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Rovi stock?

Rovi (ROVI) has a market cap of €4.35B as of April 25, 2024.

What is the P/E ratio for Rovi stock?

The price to earnings (P/E) ratio for Rovi (ROVI) stock is 25.1 as of April 25, 2024.

Does Rovi stock pay dividends?

Yes, the Rovi (ROVI) stock pays dividends to shareholders. As of April 25, 2024, the dividend rate is €1.1037 and the yield is 1.61%. Rovi has a payout ratio of 33.58% on a trailing twelve-month basis.

When is the next Rovi dividend payment date?

The next Rovi (ROVI) dividend payment date is unconfirmed.

What is the beta indicator for Rovi?

Rovi (ROVI) has a beta rating of 0.58. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Rovi stock price target?

The target price for Rovi (ROVI) stock is €75.39, which is 5.27% below the current price of €79.58. This is an average based on projections from 9 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Rovi stock

Buy or sell Rovi stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing